Naimish Patel Sells 3,150 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) insider Naimish Patel sold 3,150 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $152,019.00. Following the sale, the insider owned 13,143 shares of the company’s stock, valued at approximately $634,281.18. This represents a 19.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

CRISPR Therapeutics Stock Up 3.4%

NASDAQ CRSP traded up $1.67 during trading hours on Tuesday, hitting $50.09. The company’s stock had a trading volume of 1,870,722 shares, compared to its average volume of 1,999,385. The stock has a fifty day moving average of $53.96 and a 200 day moving average of $57.25. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The firm has a market capitalization of $4.81 billion, a P/E ratio of -7.68 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. CRISPR Therapeutics’s revenue was down 97.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.01) earnings per share. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Mcguire Capital Advisors Inc. bought a new position in CRISPR Therapeutics during the fourth quarter worth about $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics in the fourth quarter worth about $26,000. Rothschild Investment LLC raised its position in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Thompson Investment Management Inc. bought a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $33,000. 69.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. TD Cowen lifted their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Citigroup reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday. Morgan Stanley reaffirmed an “underweight” rating and issued a $33.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, February 17th. Finally, Bank of America cut their price target on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $64.53.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.